Summary
This course will help you understand the clinical aspects of pharmacovigilance in support of clinical trials, as well as the data support offered from the preclinical safety studies. You will also learn about decisions for safety margins and first-dose-in-man, safety principles in phase I, II and III studies, and regulations for safety assessments.
After the course, you will be able to understand what preclinical studies and data are created to support pharmacovigilance and how this data may be interpreted. You will be able to analyse the different application tasks related to preparing clinical trial study protocols, principles of safety reporting in clinical trials, i.e. adverse events, SUSARs, annual safety reports, and scientific advice in relation to the preparation of clinical trial applications (e.g. endpoints, statistical power, and safety parameters) as well as the pre-application tasks related to conducting clinical studies.
OTHER COURSE PARTICIPANTS SAY:
"It was a very good course. Well-prepared and with good lectures. It gives a good understanding of the pre-cinical phase which is relevant for assessing data when working in PV."
Dorte Engebjerg, Global Pharmacovigilance, Ferring Pharmaceuticals
Keywords
- Pre-clinical Safety Studies
- Drug Development
- Clinical Safety Studies
- Risk Assessment
- Pharmacovigilance in Clinical Trials
- Drug Safety
- Regulatory Affairs
- Health research ethics
Hi!
Do you need help choosing the right course?
We are ready to help you at +45 39 27 60 60 or contact@atriumcph.com
Course leader(s) & Lecturer(s)
- Allan Dahl RasmussenCourse leaderDirector, Head of Regulatory Toxicology & Safety Assessment
H. Lundbeck A/S - Lise AagaardCourse leaderSenior Legal Advisor (PhD) Council of Bioethics & Nat. Committee on Health Research Ethics
Sundheds- og Ældreministeriet - Mikael ElanderLecturerSenior Toxicologist
Zealand Pharma A/S - Henrik Friberg-JohansenLecturerPrincipal Toxicologist
H. Lundbeck A/S - Morten LaursenLecturerPhD, Principal Specialist
Novo Nordisk A/S - Karin Sørig HougaardLecturerSenior Research Scientist, Affiliate Professor in Reproductive Toxicology
National Research Centre for the Working Environment - Fida IssaLecturerSafety Surveillance Specialist
Novo Nordisk A/S - James HigginsonLecturer
Y-mAbs Therapeutics A/S - Andrew MakinLecturerCEO
Andrew Makin Preclinical Consulting ApS - Louise OtzenLecturerPrimary Toxicologist
H. Lundbeck A/S - Dorte JarmarkLecturerSenior Event Adjudication Professional
Novo Nordisk A/S - Jette Buch ØstergaardLecturerSpecialist, Clinical Pharmacology
H. Lundbeck A/S - Karina PhonekeoLecturerSenior Safety Surveillance Adviser
Novo Nordisk A/S - Lone Fjord-LarsenLecturerSenior Director, Nonclinical Development
Hoba Therapeutics ApS
IS THIS COURSE FOR YOU?
Whether you are new to the field or have several years of experience, this programme is relevant if you are a pharmacovigilance professional who wants to improve your knowledge and skills.
What you will learn
- Why preclinical safety studies are performed. What preclinical data is available to support safety assessments. How this data may be interpreted
- The rationale behind dose selection for first-dose-in-man trials and the reasoning behind decisions for safety margins
- The principles of safety monitoring in clinical phase I, II and III studies and regulations for the assessment and monitoring of safety issues in clinical studies
- How to share and discuss knowledge on preclinical and clinical aspects of pharmacovigilance from medical and ethical points of view
What your company will get
- A safety and pharmacovigilance professional who understands why preclinical safety studies are done and what preclinical data can be used for in clinical safety assessments
- A safety and pharmacovigilance professional who understands the relationship between pharmacovigilance and the processes of submission of clinical trials applications to health authorities and ethics committees.
- A safety and pharmacovigilance professional that can independently analyse and evaluate the steps in regulating drug safety
- A safety and pharmacovigilance professional who can provide valuable input to all other team members working with preclinical and clinical aspects of pharmacovigilance
Course calendar
DAY 1
- Welcome and introduction
PART 1 – Non-clinical studies leading to Phase 1 clinical trials
Overview of the non-clinical development of pharmaceutical compounds
Pathology – the gold standard in the repeat-dose toxicity studies
Genotoxicity – the discipline that covers many areas
Safety pharmacology – addressing unwanted pharmacological effects
Workshop 1 – Findings prior to going into man
Biologics – The same as small molecules?
- Summery of day 1 and introduction to day 2
DAY 2
- Introduction
PART 2 – Non-clinical studies leading from Phase 1 to marketing and beyond.
- Reproductive toxicity – the discipline that was started by terrible findings
Carcinogenicity – a long-term unwanted side effect
Other aspects of toxicological assessment and introduction to the clinical development plan
Workshop 2 – Findings during clinical development
PART 3: Safety monitoring and surveillance in Phase I- III clinical trials
- Safety considerations with respect to FIH
- Exam info, summery of day 2 and introduction to day 3
DAY 3
- Introduction
- Principles of safety in phase III studies
Workshop
- Safety reporting in clinical trials
- Data Monitoring Committee, incl. case study
- Event Adjudication Committee
- Ethical approval of clinical trials
- Kahoot quiz
- Evaluation, feedback and goodbye for now
Registration
Registration deadline8 Nov 2022
Lersø Parkallé 101
2100 København Ø
Course information
Literature
Prior to the course you will get access to mandatory and optional readings via your personal Atrium log-in.
Please familiarize yourself with the mandatory readings before starting the course.
The mandatory readings are also part of the examination syllabus.
Prerequisites
To enroll in this course, you must have a relevant educational background at bachelor level and, as a minimum, two years of experience in drug safety or pharmacovigilance, or other equivalent qualifications. We consider all applications upon registration.
If you do not fulfill the requirements, you can still apply for the course if you have suitable experience in the pharmaceutical/biological area that would allow you to benefit from the training and enable you to participate actively during the module. Up to 10% of the positions on our course are filled by applicants who have no or limited experience in drug safety or pharmacovigilance. We consider applicants on a case-by-case basis.
Examination
The exam is held online, usually 4-6 weeks after the course.
You will receive a link with exam questions via your personal Atrium log-in.
In order to participate in the exam, you must have attended the course.
This course is a part of this programme
The demand for qualified pharmacovigilance professionals is high. Become a sought after and highly valued professional by attending our pharmacovigilance training and acquire the Pharmacovigilance Diploma
Read moreCourse leader(s)
H. Lundbeck A/S
Sundheds- og Ældreministeriet
Lecturer(s)
Zealand Pharma A/S
H. Lundbeck A/S
Novo Nordisk A/S
National Research Centre for the Working Environment
Novo Nordisk A/S
Y-mAbs Therapeutics A/S
Andrew Makin Preclinical Consulting ApS
H. Lundbeck A/S
Novo Nordisk A/S
H. Lundbeck A/S
Sundheds- og Ældreministeriet
H. Lundbeck A/S
Novo Nordisk A/S
Hoba Therapeutics ApS
You may also be interested in these courses
Want to know more or need help?
Contact Educational Programme Leader Lone Rex at +45 20 62 11 46
Send me a message